Navigation Links
Pharmasset to Present at Canaccord Adams Conference
Date:8/5/2009

tment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates: RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys(R) plus Copegus(R) and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates are PSI-7851, an unpartnered, next generation HCV nucleotide analog which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial.

Pegasys((R)) and Copegus((R) )are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche w
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
4. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
5. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
8. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
9. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
10. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
11. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... (PRWEB) September 02, 2014 PMG ... its 11th clinical research site: PMG Research of Rocky ... and operation of the clinical research department at ... PMG’s presence in eastern North Carolina. This new site ... the patients in Rocky Mount and the surrounding communities, ...
(Date:9/1/2014)... Reportlinker.com announces that a new market ... India Solid Waste Management Vehicles Market Forecast ... In India ... responsible for complete handling and regulation of solid ... 135,000 MT solid waste is generated daily in ...
(Date:8/31/2014)... September 01, 2014 Available spectra ... needs for research and cultivation of a wide ... Valoya’s proprietary LEDs with proven patented and pending ... uncompromised light uniformity in critical applications in contrast ... LEDs. , “Our customers have a large variety ...
(Date:8/29/2014)... Aug. 29, 2014  Pfenex Inc. (NYSE MKT: ... development of high-value and difficult to manufacture proteins ... and reported financial results for the second quarter ... successful completion of our initial public offering, we ... biosimilar product candidates, derived from our proprietary protein ...
Breaking Biology Technology:PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... ... is excited to announce its latest product offering, PrescriberPRO Mobile. ,PrescriberPRO Mobile ... Solutions’ full database of over 1,000,000 medical prescribers. The application will provide names, ... the United States. , ...
... Lectures ... will be presented at the upcoming ICAD & 3rd ECAA Asia conference. Dr. W. ... Yu will present his latest clinical data showing successful reduction of acne using TriPollar. ... (PRWEB) January 20, 2010 ...
... strengthen host defences could be used to treat inflammatory bowel ... treatment for IBD to date, as explained in a review ... Medical Microbiology . IBD is inflammation of the gastro-intestinal ... pain. It is an emerging disease that affects 20 out ...
Cached Biology Technology:Healthcare Data Solutions Announces New Mobile Application, PrescriberPRO Mobile 2Healthcare Data Solutions Announces New Mobile Application, PrescriberPRO Mobile 3TriPollar Technology Clinically Proven to Significantly Reduce Stretch Marks and Acne 2TriPollar Technology Clinically Proven to Significantly Reduce Stretch Marks and Acne 3Promising probiotic treatment for inflammatory bowel disease 2
(Date:9/2/2014)... everyone has a tipping point. We all want to be ... is great enough. Now, scientists have confirmed the area of ... The result was published online this week in ... even if lying is beneficial," said Lusha Zhu, the study,s ... Tech Carilion Research Institute , where she works with Brooks ...
(Date:9/2/2014)... Bavaria, the Tithonian Konservat-Lagersttte of lithographic limestone is ... of emblematic fossils from that area (for example, ... found fossil insects in the French equivalent of ... species representing the oldest known water treader. , ... Bavarian outcrops, fewer fossils have been obtained from ...
(Date:9/1/2014)... the U.S. diet showed some modest improvement in the ... in the consumption of unhealthy trans fats, but the ... and the poor. , , An unhealthy diet is ... Eating a healthy diet is an important part of ... trends in diet quality is important because it can ...
Breaking Biology News(10 mins):Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Exceptionally well preserved insect fossils from the Rhône Valley 2Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... researchers at The Johns Hopkins University School of Medicine reveal ... papers appear in the March issue of The Journal ... opening, many ion channels spontaneously close by inactivation, a process ... channels is important for a variety of biological processes, including ...
... Illinois study touts the benefits of soluble fiberfound in ... the inflammation associated with obesity-related diseases and strengthens the ... immune cellsthey go from being pro-inflammatory, angry cells to ... infection," said Gregory Freund, a professor in the U ...
... NEW ORLEANS, LA. Minerals Management Service (MMS) ... biologists have set sail to learn more about the ... Mexico. The first of the research cruise,s three legs ... is underway. The first and second legs of ...
Cached Biology News:An apple a day? Study shows soluble fiber boosts immune system 2An apple a day? Study shows soluble fiber boosts immune system 3MMS and NOAA scientists study prey of Gulf of Mexico sperm whales 2
... Monoclonal Mouse Antibody to Cytokeratin 5 / ... a high molecular weight, basic type of ... the superficial cell layers of stratified epithelia ... and in mesothelial cells and mesothelioma. Cytokeratin ...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
Biology Products: